Australia buys ventilators fearing flu pandemic:
This article was originally published in Clinica
Executive Summary
Australia has spent Aus$6.2m (US$4.6m) to purchase 303 ventilators and is negotiating the purchase of 11 more. The investment is to ensure that hospitals have sufficient resources in case of an influenza pandemic, which would produce a high incidence of severe breathing disorders. The machines - some portable and some for use in intensive care units - were sourced from Melbourne-based medtech company Draeger Medical Australia. The further 11 will be portable machines. The number of ventilators given to each state and territory was determined by number of patients. The government has pledged Aus$180m over five years to prepare and respond to the potential threat.
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.